Invivyd, Inc. (IVVD)
0.4578
+0.01
(+2.67%)
USD |
NASDAQ |
Nov 20, 09:39
Invivyd Cash from Operations (Quarterly) : -32.11M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -32.11M |
| June 30, 2026 | -43.00M |
| March 31, 2026 | -41.71M |
| December 31, 2025 | -15.46M |
| September 30, 2025 | -8.25M |
| June 30, 2025 | -13.30M |
| March 31, 2025 | -21.13M |
| December 31, 2024 | -37.61M |
| September 30, 2024 | -41.07M |
| June 30, 2024 | -41.60M |
| March 31, 2024 | -50.21M |
| December 31, 2023 | -59.24M |
| Date | Value |
|---|---|
| September 30, 2023 | -35.35M |
| June 30, 2023 | -37.39M |
| March 31, 2023 | -41.18M |
| December 31, 2022 | -47.40M |
| September 30, 2022 | -56.14M |
| June 30, 2022 | -57.39M |
| March 31, 2022 | -59.05M |
| December 31, 2021 | -73.21M |
| September 30, 2021 | -54.21M |
| June 30, 2021 | -33.57M |
| March 31, 2021 | -23.74M |
| December 31, 2020 | -13.43M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Lineage Cell Therapeutics, Inc. | -5.62M |
| Armata Pharmaceuticals, Inc. | -5.516M |
| Voyager Therapeutics, Inc. | -19.67M |
| Black Diamond Therapeutics, Inc. | -8.338M |
| Elicio Therapeutics, Inc. | -10.36M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.585M |
| Cash from Financing (Quarterly) | 0.028M |
| Free Cash Flow | -134.11M |
| Free Cash Flow Per Share (Quarterly) | -0.1014 |
| Free Cash Flow to Equity (Quarterly) | -32.56M |
| Free Cash Flow to Firm (Quarterly) | -32.70M |
| Free Cash Flow Yield | -99.09% |